EGFR and neoplasm: Nowadays, the well-known genetic mutations like O6-methylguanine methyltransferase (MGMT) promoter methylation, which is associated with a significantly higher median survival after therapy with TMZ [23] and other molecular tumor biomarkers, such as epidermal growth factor receptor (EGFR) amplification, aldehyde dehydrogenase 1A3 (ALDH1A3) and isocitrate dehydrogenase (IDH1/IDH2) isoforms are currently foci of research and were also linked to prognosis [22,24].